Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis

Cancer Research

Volumn 69, Issue 17, 2009, Pages 7038-7045

  Saini, Sharanjot ^a   Hirata, Hiroshi ^a   Majid, Shahana ^a   Dahiya, Rajvir ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BINDING PROTEIN; BINDING PROTEIN CEBP1; CD146 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLIN E1; CYTOCHROME P450 1B1; GRANZYME A; MINICHROMOSOME MAINTENANCE PROTEIN 4; RAD51 PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN E; CYTOCHROME P-450 ENZYME SYSTEM; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-BETA; ONCOGENE PROTEINS; RNA, SMALL INTERFERING; S-PHASE KINASE-ASSOCIATED PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 70149107045     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1691     Document Type: Article

References (49)

1. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994;26:165-183
2. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991;4:391-407.
3. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, Kadlubar FF. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem 2001;49:229-236
4. Tang YM, Chen GF, Thompson PA, Lin DX, Lang NP, Kadlubar FF. Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1. Drug Metab Dispos 1999;27:274-280
5. Savas U, Christou M, Jefcoate CR. Mouse endometrium stromal cells express a polycyclic aromatic hydrocarbon-inducible cytochrome P450 that closely resembles the novel P450 in mouse embryo fibroblasts (P450EF). Carcinogenesis 1993;14:2013-2018 (Pubitemid 23311425)
6. Sutter TR, Tang YM, Hayes CL, et al. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 1994;269:13092-13099
7. Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006;4:135-150
8. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A 1996;93:9776-9781 (Pubitemid 26296685)
9. Liehr JG. Genotoxic effects of estrogens. Mutat Res 1990;238:269-276
10. Han X, Liehr JG. DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 1994;15:997-1000. (Pubitemid 24156901)
11. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000;60:235-237
12. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026-3031 (Pubitemid 27315056)
13. McKay JA, Melvin WT, Ah-See AK, et al. Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett 1995;374:270-272
14. Tokizane T, Shiina H, Igawa M, et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 2005;11:5793-5801 (Pubitemid 41170305)
15. McFadyen MC, Cruickshank ME, Miller ID, et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 2001;85:242-246 (Pubitemid 32695746)
16. Lohr M, McFadyen MC, Murray GI, Melvin WT. Cytochrome P450 enzymes and tumor therapy. Mol Cancer Ther 2004;3:1503; author reply 1504.
17. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 2001;62:207-212 (Pubitemid 32522940)
18. McFadyen MC, Melvin WT, Murray GI. Cytochrome P4507 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004;3:363-371
19. Marx J. How cells cycle toward cancer. Science 1994;263:319-321 (Pubitemid 24067936)
20. 1 cyclins and cell cycle progression. Proc Assoc Am Physicians 1995;107:181-186
21. 1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163
22. 1-to-S phase transition. Mol Cell Biol 1995;15:2612-2624
23. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008;112:1415-1424
24. Reed SI. Deathproof: new insights on the role of skp2 in tumorigenesis. Cancer Cell 2008;13:88-89 (Pubitemid 351175660)
25. Kitagawa M, Lee SH, McCormick F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell 2008;29:217-231 (Pubitemid 351172826)
26. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13:41-47 (Pubitemid 36269179)
27. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol 2008;61:36-42. (Pubitemid 351158223)
28. Kamata Y, Watanabe J, Nishimura Y, et al. High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma. J Cancer Res Clin Oncol 2005;131:591-596 (Pubitemid 41558552)
29. Lahav-Baratz S, Ben-Izhak O, Sabo E, et al. Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not in normal secretory or in hyperstimulated endometrium. Mol Hum Reprod 2004;10:567-572 (Pubitemid 39136815)
30. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-163 (Pubitemid 41351311)
31. Wu GS. TRAIL as a target in anti-cancer therapy. Cancer Lett. Epub 2009 Mar 17.
32. Sadarangani A, Kato S, Espinoza N, et al. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis 2007;12:73-85. (Pubitemid 46009505)
33. Nishida M, Kasahara K, Oki A, Satoh T, Arai Y, Kubo T. Establishment of eighteen clones of Ishikawa cells. Hum Cell 1996;9:109-116
34. Way DL, Grosso DS, Davis JR, Surwit EA, Christian CD. Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro 1983;19:147-158
35. Kuramoto H. Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet Gynaecol Jpn 1972;19:47-58.
36. Richardson GS, Dickersin GR, Atkins L, et al. KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol Oncol 1984;17:213-230 (Pubitemid 14193208)
37. Cassia R, Moreno-Bueno G, Rodriguez-Perales S, Hardisson D, Cigudosa JC, Palacios J. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol 2003;201:589-595 (Pubitemid 38256408)
38. Spruck CH, Strohmaier H, Sangfelt O, et al. hCDC4 gene mutations in endometrial cancer. Cancer Res 2002;62:4535-4539 (Pubitemid 34898570)
39. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-225
40. Ishimi Y, Okayasu I, Kato C, et al. Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. Eur J Biochem 2003;270:1089-1101 (Pubitemid 36384443)
41. Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 2008;7:686-693
42. Mitsui K, Nakanishi M, Ohtsuka S, et al. A novel human gene encoding HECT domain and RCC1-like repeats interacts with cyclins and is potentially regulated by the tumor suppressor proteins. Biochem Biophys Res Commun 1999;266:115-122 (Pubitemid 30028777)
43. Lindner DJ, Borden EC. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J Interferon Cytokine Res 1997;17:681-693
44. Wong JJ, Pung YF, Sze NS, Chin KC. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci U S A 2006;103:10735-10740
45. Moffitt KL, Martin SL, Walker B. The emerging role of serine proteases in apoptosis. Biochem Soc Trans 2007;35:559-560 (Pubitemid 46975075)
46. Martinvalet D, Dykxhoorn DM, Ferrini R, Lieberman J. Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell 2008;133:681-692 (Pubitemid 351636303)
47. Johnson JP, Rummel MM, Rothbacher U, Sers C. MUC18: a cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Curr Top Microbiol Immunol 1996;213:95-105. (Pubitemid 26168563)
48. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2003;2:S38-47.
49. Mazumder S, DuPree EL, Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets 2004;4:65-75. (Pubitemid 38332565)